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Objectives: To conduct a systematic review of literature in on epidemiology and 
economic studies for patients diagnosed with Non-Psychotic Major Depressive 
Disorder (MDD). MethOds: The initial search strategy was developed in the 
PubMed/Medline database, and was then translated for the Cochrane and Embase 
database searches. Search strings for epidemiology and economics studies for MDD 
were constructed using varied approaches that included the use of MeSH terms, 
as well as keywords that would afford the best retrieval. Search statements were 
then combined to produce a final search set. Additional parameters were placed on 
the final search strategy to limit the retrieval to articles written in English, involv-
ing human subjects and published between 2000 and 2010. Results: Our search 
revealed 289 articles for epidemiology and 200 articles for economic studies on 
MDD from PubMed/Medline/Embase/Cochrane databases. After removing dupli-
cates and non-relevant articles, 17 for epidemiology and 26 for economic studies 
were included in the final analysis. Fifteen studies on epidemiology were focused 
on MDD prevalence, one study was on cumulative incidence. Prevalence estimates 
were higher for lifetime than past year and ranged between 3.1% and 26.6% for life-
time prevalence and between 1.5% and 11.7% for past-year prevalence. Two studies 
examined burden of illness, one study budgetary impact of MDD, 14 studies exam-
ined cost effectiveness of MDD treatments, 3 studies examined cost utility analysis 
and 6 other studies examined retrospective claims analysis. cOnclusiOns: MDD 
prevalence was higher in the lifetime estimates, when compared to the estimates 
reflecting shorter time frames, although there appeared to be greater variability in 
the lifetime estimates. Overall, the cost of treating MDD varied with type of study, 
study time frame, study perspective, the year in which the costs were calculated, 
and the pharmacotherapy prescribed.
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Objectives: To perform a systematic review of literature in peer-reviewed 
journals on clinical biomarkers, correlates and treatment efficacy in clinical 
studies on patients diagnosed with Non-Psychotic Major Depressive Disorder 
(MDD). MethOds: The initial search strategy was developed in the PubMed/Medline 
database and was then translated for the Cochrane and Embase database searches. 
Search strings for biomarkers, correlates and treatment efficacy in patients with 
MDD were constructed using varied approaches that included the use of MeSH 
terms, as well as keywords that would afford the best retrieval. Also included were 
search terms that used an asterisk as a wildcard applied to a word stem. Search 
statements were then combined to produce a final search set. Additional parameters 
were placed on the final search strategy to limit the retrieval to articles written in 
English, involving human subjects and published between 2000 and 2010. Results: 
The initial search revealed 871 articles from PubMed/Medline/Embase/Cochrane 
databases. After removing duplicates and non-relevant articles, the final articles 
that were included in the review were 131. Forty-eight studies examined biomarkers 
and primarily focused on the relationship between biomarkers and MDD treat-
ment response. Only 29 of the 48 studies found a significant association between a 
biomarker and treatment response. Twenty-nine studies examined MDD correlates 
such as comorbidity or demographic variables. A poorer response to treatment was 
found for those patients who experienced comorbid anxiety, irrespective of the 
type of treatment. Fifty-four studies focused on treatment efficacy and are divided 
into 3 groups: SSRIs only, SNRIs only, and a comparison across SSRIs, SNRIs, and 
bupropion. Overall, the SSRIs showed comparable efficacy when compared to each 
other or placebo. cOnclusiOns: Most of the biomarker studies examined associa-
tions between the serotonin transporter and response to various MDD treatments. 
The majority of efficacy studies found that the treatments that are within the class 
had comparable efficacy.
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Objectives: Antipsychotics polypharmacy (AP) has been associated with more 
adverse drug effects, higher treatment costs, worse clinical outcomes and sudden 
death. Though, the frequency of such practice may reach 50 % in some clinical set-
tings. The aims of this study were to estimate AP costs and its influence on the direct 
costs of health care package in a sample of people with mental disorders in São Paulo 
city, Brazil. MethOds: We used a bottom-up approach for the estimation of direct 
costs according to public health service provider perspective. Direct costs included 
costs with accomodation (residential service), inpatient, outpatient and emergency 
services and treatment received in the previous month, in 147 subjects with mental 
disorders living in twenty residential services during the year 2011. We evaluated 
quality of life, social behavior problems, psychiatric diagnosis, severity of symptoms, 
sociodemographics characteristics and pattern of health service use. Results: AP 
was found in 38% of the sample and it was not related with gender, age, severity of 
psychiatric symptoms, quality of life and social behavior problems. Antipsychotics 
monotherapy costs were related with the type of antipsychotic: Atypical antipsychot-
vant articles, the final articles that were considered for review were 82 for treat-
ment response and 13 for risk factors. Fifty-one studies examined non-genetic 
factors, serotonin-related genetic factors and variety of genes and polymorphism 
biomarkers to determine their association with MDD treatment response. Thirty-
one studies focused on variables that were found to be associated with some 
aspect of MDD and their impact on treatment response and include: comor-
bidity (n= 12), demographic and socioeconomic (n= 6), and depression-related 
(n= 13) variables. Thirteen studies examined the risk factors for MDD. Of these, 2 
studies focused on the role of biomarkers in MDD risk. And, 11 studies focused 
on variables that were found to be associated with some aspect of MDD and 
their impact on MDD risk, and focused on comorbidity (n= 5), demographic and 
socioeconomic (n= 2), depression-related (n= 3), and environmental variables 
(n= 1). cOnclusiOns: The majority of the biomarker studies examined associa-
tions between the serotonin transporter, genes and polymorphisms in response 
to various MDD treatments. With respect to correlate studies, younger age of MDD 
onset, as well as family history of mood disorders, were both associated with a 
longer duration of MDD illness.
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Objectives: This research uses propensity score methods to identify the relation-
ship between amount of treatment and treatment outcome for adolescents with 
psychoactive substance use disorder (PSUD). The objective is to describe the dose 
response relationship in terms relevant in economic evaluation. Outcomes studies 
in this population show that longer treatment leads to more positive outcomes. 
The standard for residential programs is a minimum of 21 days of treatment and 
ideally up to 90 days. MethOds: The subjects are 377 adolescents who success-
fully completed primary treatment from 2004-2010. All were placed at ASAM level 
III.5 (Clinically-Managed, Medium/High Intensity Residential). The data are from 
treatment records and a 234-item questionnaire. The questionnaire responses were 
matched to variables in treatment records creating a rich source of pre-treatment 
characteristics. This research operationalizes dose with four one-month categories 
(1 dose= 1 month) to capture nonlinearities between service use and outcomes. The 
outcome is three-month post-treatment drug/alcohol abstinence. The categories 
were fairly even and captured 92% of variation in dose. The first stage of statistical 
analysis used multinomial logistic regression to predict dosage with pre-treatment 
variables while adjusting for characteristics influencing both dose and treatment 
outcome. Propensity scores were then created for each dosage category. The dose 
response relationship was assessed using a binomial logistic regression includ-
ing the four dose categories as dummy variables (lowest dose category as refer-
ence). Results: The overall relationship between dose and outcome was significant 
(p= 0.01) as were outcome improvements over the four doses. Improvements were 
significant (p≤ 0.01) decreasing as dose increased—Exp.(B) was1.204 (1.2 times 
more likely to abstain) for one month, 1.532 two months, 1.643 three months, and 
1.794 for four months (% correctly classified= 94.2; – 2LL= 44.712; Cox and Snell 
R2= 0.475.) cOnclusiOns: This research shows a significant dose response rela-
tionship between treatment length and treatment outcome with response dimin-
ishing on the margin.
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Objectives: To compare treatment outcomes in patients with major depressive dis-
order (MDD) treated with either duloxetine or a selective serotonin reuptake inhibi-
tor (SSRI) for up to 6 months in a naturalistic setting in Mexico. MethOds: Data in 
this post hoc analysis were taken from a 6-month prospective, non-interventional, 
observational study that included a total of 1,549 MDD patients without sexual 
dysfunction in twelve countries (N= 591 in Mexico). Depression severity was meas-
ured using the Clinical Global Impression (CGI) and the 16-item Quick Inventory of 
Depressive Symptomatology Self-Report (QIDS-SR16). Pain was measured using the 
pain related items of the Somatic Symptom Inventory (SSI), and quality of life (QoL) 
was measured using the EQ-5D instrument with the UK population tariff and the 
EQ-VAS. Probabilities of initiating duloxetine (vs. SSRIs), expressed as propensity 
scores, were first constructed using logistic regression. Mixed effects modelling 
with repeated measures (MMRM) analysis was then used to compare treatment 
effectiveness and QoL between the duloxetine (N= 168) and SSRI (N= 413) groups, 
controlling for the propensity scores and other patient characteristics. Results: 
The severity of depression was comparable between the two groups at baseline. 
Duloxetine-treated patients, however, had a higher level of pain severity and a 
lower level of QoL (EQ-5D) than SSRI-treated patients at baseline (p≤ 0.001). Both 
descriptive and MMRM regression analyses showed that patients treated with dulox-
etine had better outcomes during follow-up, compared with patients treated with 
SSRIs. At 6 months, duloxetine-treated patients had lower levels of CGI (2.25 vs. 
2.52, p= 0.005), QIDS-SR16 (3.95 vs. 5.35, p< 0.001), and SSI-pain related (8.52 vs. 9.64, 
p< 0.001), and higher levels of EQ-5D (0.92 vs. 0.87, p< 0.001) and EQ-VAS (64.62 vs. 
57.63, p= 0.006) (MMRM results). cOnclusiOns: Duloxetine-treated patients had 
better 6-months outcomes in terms of depression severity, pain and QoL, compared 
with SSRI-treated patients.
